Drug Profile
INCAGN 1949
Alternative Names: Anti-OX40-monoclonal-antibody- Incyte Corporation; INCAGN-01949; INCAGN-1949Latest Information Update: 20 Feb 2023
Price :
$50
*
At a glance
- Originator Agenus; Ludwig Institute for Cancer Research
- Developer Agenus; Incyte Corporation
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; OX40 receptor agonists; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Pancreatic cancer; Solid tumours
Most Recent Events
- 20 Feb 2023 Discontinued - Phase-I for Pancreatic cancer in USA (Parenteral) prior to February 2023 (Agenus website, February 2023)
- 20 Feb 2023 Discontinued - Phase-I/II for Solid tumours (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IV) prior to February 2023 (Incyte Corporation, February 2023)
- 20 Feb 2023 Discontinued - Phase-I/II for Solid tumours (Late-stage disease, Metastatic disease) in Spain, USA, Switzerland, United Kingdom (Parenteral) prior to February 2023 (Agenus website, February 2023) (Incyte Corporation, February 2023)